Lattice Medical announces the closing of a €8 million Series A financing round

LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt from BPIFrance and the EIC accelerator.

On the way to clinical trials
The first objective of this financing round is the completion of the pre-market clinical evaluation of the MATTISSE implant. The clinical trial, started in July 2022 and plans to recruit 50 patients eligible for immediate breast reconstruction in 8 centers in Europe. This clinical trial will last 36 months and will lead to CE marking. This clinical investigation called TIDE, had a first successful implantation by 12th of July at the Institute of Clinical Oncology with a 63 years old patient operated with MATTISSE in the case of her breast cancer and immediate reconstruction.

CE marking, industrialisation and hiring for the marketing of MATTISSE
The second objective of this fundraising is to obtain the CE mark and to start sales of the MATTISSE implant. For this, LATTICE MEDICAL plans to hire a dozen people between now and 2024, particularly in production, marketing, communication and sales. The fundraising will also allow to upgrade and expand the current pilot production equipment set up by the company 2 years, ahead of the commercial launch.

Consolidate R&D efforts and the development of new products In order to sustain its investments and production equipemnt, LATTICE MEDICAL is consolidating its R&D effort and developing other healthcare products using 3D printing for tissue reconstruction. In particular, the implantable medical device RODIN is being developed, capable of repairing deep skin lesions, common among soldiers, linked to trauma caused by explosions or firearms for example. Through its brand LATTICE SERVICES, we reinforce the marketing of our medical filaments for 3D printing.

LATTICE MEDICAL is an implantable medical device company that develops and manufactures a breakthrough resorbable implant supporting reconstruction with one’s own body fat (“ autologous fat reconstruction”). The company has about 20 employees and a 3D printing production site dedicated to implantable medical devices.

The first application of its technology is for breast reconstruction after cancer. Currently, one out of woman gets sooner or later breast cancer. In 40% of cases, the treatment is surgical with a complete or partial mastectomy. The current reconstruction techniques (breast implants or autologous surgical techniques) require cumbersome, multiple, costly surgical procedures so that only 14% of women get a reconstruction. LATTICE MEDICAL’s medical implant “MATTISSE” has the potential to change this radically. It allows the regeneration of autologous fatty tissue and is completely resorbed by the body after breast reconstruction, thus avoiding additional surgeries and long-term consequences and risks for patients.